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Abstract
Objectives The aim of this study was to assess serum tumor
necrosis factor alpha (TNFA) concentrations 8 months of
continuous positive airway pressure (CPAP) therapy.
Design This study used prospective, observational clinical trial.
Patients Sixty-six patients with newly diagnosed sleep
apnea syndrome (12 women, 54 men), age 52.3±9.8
(mean±SD) with a body mass index of 29.7±4.4 and an
apnea-hypopnea index of 39.7±26.8, were studied.
Intervention CPAP was administered for a mean of 7.8±
1.3 months.
Measurements and results TNFA concentrations using an
ultrasensitive ELISA assay at baseline and follow-up.
TNFA decreased in men with high (5.2±1.7 h/night,
−0.46±1.1 ng/l, p=0.001) and with low (2.5±1.0 h/night
−0.63±0.77 ng/l, p=0.001) adherence but not in women.
Average number of hours of CPAP use correlated
positively with delta TNFA (R2 0.08, p=0.04)
Conclusion Long-term CPAP positively affects TNFA even
in men with poor adherence to CPAP.
Keywords Obstructive sleep apnea syndrome . CPAP.
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Introduction
Proinflammatory cytokines such as tumor necrosis factor
alpha (TNFA) play an important role as physiologic
regulators of human sleep [1]. Obstructive sleep apnea
syndrome (OSAS) is characterized by frequent disruptions
of sleep [2] and leads to an alteration of the circadian
rhythm of TNFA concentrations with a shift from nocturnal
peaks to daytime peaks thereby aggravating daytime
sleepiness [3]. Several reports have suggested that OSAS
is associated with an increased proinflammatory activity
indicated by elevations of C-reactive protein (CRP) [4],
TNFA, and interleukin 6 (IL-6) [5, 6]. Current research
suggests that one factor contributing to increased inflamma-
tory activity is visceral adipose tissue [7].
Three weeks of administration of a TNFA antagonist
significantly decreased TNFA serum concentration and
daytime sleepiness in OSAS patients [8] and therapy of
OSAS with nasal continuous positive airway pressure
(CPAP) decreased serum TNFA concentrations after 4 [9],
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8 [10], and 12 weeks [11]. Furthermore, short-term CPAP
use significantly reduced visceral fat mass [12], thus
potentially affecting TNFA-producing tissue. In contrast,
we and others [13, 14] were not able to reproduce such an
effect using a different imaging method. Thus, the
contribution of visceral fat mass to TNFA concentrations
in patients with OSAS remains unclear.
While a recent study reported a significant decline in
CRP concentration [15] with a steep decline after three and
a plateau after 6 months, little is known on the effects of
longer-term CPAP therapy on TNFA. In addition, the
contribution of other clinically relevant parameters such as
disease severity and compliance with CPAP on changes in
TNF concentrations in OSAS patients has not been
examined.
In the current study, we aimed to examine if CPAP use
of more than 6 months would decrease TNFA levels in
women and men with newly diagnosed sleep apnea
syndrome independent of relevant changes in adipose
tissue.
Methods
Inclusion and exclusion criteria
A detailed description of our study population has been
published previously [13]. In brief, patients with diabetes
and hypercholesterolemia were included if on stable (oral)
medication. None of the study participants had active
inflammatory disease. There was no change in medication
throughout the study period. Patients with pituitary disease,
untreated thyroid disease, medication known to interfere
with TNFA levels, and patients with elective surgery
(such as gastric banding or hip replacement) within
6 months after enrolment were also not eligible. All
patients were asked to keep their diets and their level of
physical activity constant during the study period. This
recommendation was given at baseline and reinforced at
a follow-up visits after 1 and 3 months of CPAP. Written
informed consent was obtained from all participants. The
protocol had been approved by the Kanton St. Gallen
Ethics Committee.
Patients were scheduled for an outpatient visit with one of
the physicians in the sleep center. Prior to this appointment,
they routinely completed a set of questionnaires. Covered
domains were socio-demographic data, assessment of
smoking status and alcohol use, a validated German
version of the Epworth Sleepiness Scale (ESS) [16], and
the Stanford Sleep Disorders Questionnaire [17]. During
the appointment, each patient had a complete medical
history to assess comorbidities [18] such as hypertension,
coronary heart disease, diabetes, hypercholesterolemia,
active inflammatory disease, and current medications.
Based on the original paper, information on comorbidities
were scored, and we calculated a summary score for each
patient. Physical examination included inspection of the
oropharynx and auscultation of the lungs and heart.
Patients who, based on clinical judgment and the results
of the screening questionnaires had a high likelihood to
have OSAS, were then scheduled for polysomnography
(PSG). In the evening, preceding PSG patients were asked
to participate in the study. After an overnight fast, blood
samples for baseline measurements (serum electrolytes,
glucose, creatinine) including TNFAwere drawn, independent
of the result of the sleep study. Patients with OSAS who
agreed to start on CPAP were scheduled for baseline body
composition within 2 weeks after initiation of CPAP therapy.
They received an instruction in nasal CPAP use for three
consecutive nights in the hospital (including CPAP pressure
titration with an automated device and pulse oximetry)
followed by home CPAP. Monitoring of hours of operation
of the CPAP machine was used as a measure of compliance.
After a minimum period of 6 months of CPAP, all baseline
examinations were repeated.
Materials and methods
Polysomnography
PSG data were recorded with a commercially available
monitoring system (Mepal, MAP Medizin-Technologie,
Martinsried, Germany, now, ResMed). Three channels of
electroencephalography (EEG), eyes, chin and legs electro-
myography (EMG), thoracic and abdominal effort bands, body
position, nasal pressure, nasal and oral thermistor signals and
pulse oximetry were recorded together with video signals and
acoustic data. Manual analyis with the Rembrandt software,
which combines comprehensive high-tech PSGwith flexibility
for the review and analysis of sleep, was performed. In the
evening preceding the sleep study, each participant was offered
a standardized meal at 1800 hours. Lights were turned off at
2200 hours. Minimum recording time was 6 h in order to meet
diagnostic standards. All sleep studies were analyzed by an
experienced physician. Main outcome variables for the
diagnosis of OSAS were apnea-hypopnea index (AHI) defined
as the number of apneas (>80% reduction of the flow signal
and hypopneas, >50% reduction of the flow signal accompa-
nied by a desaturation >3% or by a respiratory-induced EEG
arousal) per hour of sleep monitored and the oxygen
desaturation index (ODI) defined as the hourly rate of episodes
of arterial oxygen desaturations >3% of a stable baseline. The
severity of sleep apnea was graded as mild (5–15 events per
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hour) moderate (16–30 events per hour), and severe (>30
events per hour) [19].
Nasal CPAP-ventilation and assessment of compliance
Patients who were eligible for CPAP were instructed by
trained nurses in the sleep center. After an AutoCPAP
night (Sullivan Autoset T), a constant CPAP pressure
was set at the 90–95 percentile of pressure applied by the
AutoCPAP device. Clinical assessment by changes in
clinical symptoms, outpatient pulse oxymetry (Konica-
Minolta Pulsox 3, Anandic, Switzerland) at the patient's
home, and stored data of the CPAP device were used to
judge on the ongoing efficacy of the fixed CPAP pressure
applied. In the case of any doubts concerning efficacy, an
in-lab PSG on CPAP was performed.
In addition, one single experienced pneumonologist
(ODS) reviewed all patient charts and oximetry results.
The pulse oximetry data was evaluated by visual inspection
for consistency of the stored overnight pulse and oxygen
saturation curves. The ODI was calculated for the time
period with no artifact signals recorded in the traces of the
respective curves. Based on clinical follow-up information,
overnight oximetry data and objective compliance informa-
tion (an average of ≥4 h of CPAP use per night) was the
minimum requirement to classify a patient as compliant
[20]; patients were graded into two categories: non-
adherent and adherent.
Clinical assessment of body composition and MRI imaging
Weight was measured to the nearest 0.1 kg on a
calibrated scale and height was determined using a
wall-mounted stadiometer. Body mass index (BMI) was
calculated as the weight divided by the square of height
(kilograms per square meter). Waist circumference (WC)
was defined as the total circumference (centimeter) above
the iliac bones. Clinical body composition data were
collected from single measurements of trained nurses.
Data from abdominal MRI imaging studies from a
previous report [13] were used to describe the association
of visceral fat areas with TNFA.
Laboratory assays
The morning after PSG and after at least 6 months of
CPAP treatment between 8 and 10A.M. fasting blood
(EDTA, plasma) was drawn and kept at −80°C until
further analyses. Serum electrolytes and glucose were
assessed by an automated analyzer (Synchron, Unicel
DXC 800, Beckman Coulter, Inc., Fullerton, CA 92835,
USA) in collaboration with an ISO-certified clinical core
laboratory. Coefficient of variation (CVs) for each analysis
were ≤2%. TNFA serum concentrations were determined
with an ultrasensitive ELISAwith a sensitivity <0.17 ng/l and
a range of 1.56–100 ng/l (Invitrogen Corporation, Camarillo,
CA 93012, USA). This assay has an intra-assay CVof 5% and
an inter-assay CVof 7% respectively. Identical analyses were
redone after at least 6 months of CPAP.
Statistics
Statistical analyses were done with Stata (Stata, Stata
Corp. 2005. Stata Statistical Software: Release 9. College
Station, TX, USA). Summary statistics are described as
means and standard deviations (SD) or standard errors of
the mean (SE). Baseline associations of TNFA with
measures of disease severity were assessed with simple
linear regression analysis after log transformation where
data were skewed. Patients were first analyzed as a
whole and then divided into compliant and non-
compliant groups, and identical analyses were repeated
within each group. Finally, we used linear regression to
examine the association of ventilation and changes in
TNFA levels at the end of our study. A p value of less
than 0.05 was considered statistically significant.
Results
Patients
Out of 566 patients screened for participation, 101
patients were excluded due to language barriers. One
hundred ninety-eight patients did not give informed
consent for personal and work-related reasons (difficulty
to leave the job for additional study appointments). Non-
consenters and consenters did not differ by age, sex,
BMI, smoking status, and socio-demographic data;
however, consenters more often reported alcohol use
(215/260, 82.7% vs. 143/192, 74.5%, p=0.03) and had a
slightly higher mean ESS score (11.3±4.4 vs. 10.6±4.8, p
=0.03) (data not shown). Eight patients with diabetes on
regular oral medication (sulfonylurea or metformin) were
included. Patients were equally distributed between sever-
ity and age categories (chi-square test p=0.4, data not
shown). Ninety five of 267 patients who agreed to
participate had no indication for and, 11 patients did not
start with CPAP. Twenty eight of 161 patients who started
CPAP discontinued within the first month. A total of 51
patients opted to not participate until the final visit of the
trial; thus, a total of 82 women and men entered the final
visit. Two sets of blood samples were not available in 16
patients. We here report data on OSAS and the effects of
Sleep Breath (2012) 16:405–412 407
CPAP on TNFA serum concentrations in 66 patients (12
women, 54 men) with a mean age of 52.3±9.8 years
treated with CPAP for at least 6 months who had no
significant changes in abdominal subcutaneous fat, visceral
fat, or total body fat mass after a mean of 7.8 months of CPAP
therapy [13].
Baseline characteristics of ventilated study population
At baseline, women and men did not differ by age,
AHI, ODI, mean Charlson score, BMI, WC, and TNFA
levels. In contrast, women had significantly smaller
abdominal visceral fat areas than men (−50.6 cm2 p=
0.03). Furthermore, we found no association between
smoking status and baseline TNFA serum levels (ANOVA
F 1.79, p=0.17, data not shown). When grouped by
adherence, compliant patients had a significantly higher
baseline AHI (45±26 h−1 vs. 28±21 h−1 p=0.02), and a
higher ODI (28±27 h−1 vs. 13±9 h−1 p=0.02), while there
were no statistically significant differences regarding body
composition, comorbidity, or serum TNFA concentrations
(Table 1).
Baseline associations of body composition and PSG results
with TNFA concentration
At baseline, we found no significant associations of log
ODI or log percent time spent below an oxygen saturation
of <90% with serum TNFA concentration in any sex or
group (data not shown).
Effects of CPAP on serum TNFA by adherence
Fifty compliant patients underwent effective (nightly usage
≥4 h, mean 5.2±1.7 h) CPAP therapy over an average period of
7.8±1.3 months, whereas the mean CPAP use in 16 non-
compliant patients (3 women, 13 men) was 2.5±1.0 h (p=
0.00001) (Figs. 1 and 2). By visual inspection of the 50 TNF
pairs, we observed a TNFA increase in two individuals
(1w/1 m). Clinical chart review in these individuals
revealed no signs for active inflammation or other
reasons for such an increase at follow-up. After elimination
of these two persons, the overall mean change −0.38±0.56, (p
=0.0001) in TNF was slightly higher but still significant
when compared to the t test performed with 50 patients
−0.28±0.71, (p=0.007). We thus decided to report data on
all 50 patients. In this cohort, TNFA levels decreased
significantly in men (−0.49±0.13 ng/l; p=0.0012), but not
in women. When grouped by adherence, mean TNFA
decreased similarly in 41 compliant (−0.46±1.1 ng/l; p=
0.001) and in 13 non-compliant (−0.63±0.77 ng/l; p=0.001)
men and simple linear regression revealed a small but
significant direct association of hours of nightly CPAP use
with changes in TNFA levels (R2 0.08, p=0.04), whereas
serum electrolytes, creatinine and fasting glucose did not
change significantly at follow-up (data not shown).
Discussion
In this prospective observational study in women and
men with OSAS, we found that baseline ODI and time
spent below saturation >90% during a diagnostic PSG
were not predictive of serum TNFA concentration, and
that an average of 8 months of CPAP decreased TNFA in
men but not in women. In addition, we demonstrated that
mean serum TNFA concentrations decreased in both,
men with and without good adherence to CPAP use.
While a previous study reported a significant correlation
of TNFA levels with ODI, ESS scores, and total cholesterol
Table 1 Baseline description of study population
All (N=66) SD Women (n=12) SD Men (n=54) SD Sex difference p value
Age (years) 52.3 9.8 55.2 11.5 51.7 9.4 3.5 0.3
AHIa 39.7 26.8 30.8 30.8 41.5 25.8 −10.8 0.2
ODIb 25.1 24.6 21.0 26.0 26.0 24.5 0.5 25.1
Charlson score 0.2 0.5 0.1 0.2 0.2 0.5 0.6 0.2
BMI (kg/m2)c 29.7 4.4 31.0 6.9 29.5 3.7 1.5 0.3
Waist circumferene (cm) 104.2 10.9 106.5 109.1 103.0 83.0 3.5 0.2
Abdominal visceral Fat (cm2) 193.3 95.6 153.3 52.0 202.8 77.4 −50.6 0.03
TNFA (ng/l) 1.7 1.0 1.4 0.7 1.8 1.1 −0.4 0.2
a Apnea-hypopnea index
b Oxygen desaturation index
c Body mass index
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using a multiple regression model [21], we found no
correlation of TNFA with ODI in our patients. Although
PSG is the gold standard for the diagnosis of OSAS, data
derived from a single examination may not reflect overall
hypoxemia burden associated with this disease and, Ryan
and colleagues [21] reported that their patients were highly
selected, while our study population was recruited from an
unselected clinical population. In addition, the association
between inflammatory markers and disease severity is still
controversial given that a mean ODI of 10 h−1 did not
predict CRP and interleukin −6 levels when compared with
obese controls [22].
That an average of 8 months of CPAP decreased
TNFA in adherent men is in line with recent authors who
have reported similar changes after 1 [9] and 2 [10]
months. Effects of a comparable magnitude have been
observed in a group of men after 6 weeks of CPAP use
with an average duration of 4.5 h/night in 49 men with
mild (AHI 15±8 h−1) to severe (57±21 h−1) disease [21],
whereas another investigation did not find an effect of
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CPAP on TNFA but a decrease in soluble TNFA receptor
after 6 weeks of treatment [23]. Taken together, our data
indicate that CPAP use of up to 8 months is beneficial to
affect the inflammatory burden associated sleep apnea.
Nevertheless, two patients with good adherence had an
increase in TNFA serum concentrations for unclear
reasons. If such patients differ from those with a decrease
in TNFA remains to be determined.
In our study, an average duration of 2.5 h of CPAP use
significantly decreased mean TNFA concentrations. Given
that our non-adherent men had a lower mean AHI scores
(28±21 h−1) compared with patients with low adherence
reported from another study (63±18 h−1) [10], we speculate
that men with fewer apneas and desaturations per night
might well benefit from a shorter nightly CPAP use.
While a growing body of evidence supports a link
between OSAS and systemic inflammation [4, 24], the
underlying mechanisms are not completely understood.
In vitro studies have suggested that sustained hypoxia
leads to an activation of genes encoding proteins that
increase delivery. On the other hand, hypoxemia is
associated with the activation of transcription factors
that trigger the expression of genes that encode inflam-
matory proteins such as TNFA [25]. Reversal of hypox-
emia by CPAP thus leads to a downregulation of such
transcription factors.
Although visceral obesity may also be a contributor to
inflammation in OSAS [26], data on the effects of CPAP on
visceral adipose tissue and inflammatory cytokines are
sparse. Authors have either published a reduction in
visceral fat mass after CPAP without data on inflammatory
cytokines [12] or changes in cytokines without addressing
visceral fat [9, 23, 27].
While we reported earlier that visceral fat mass was
unaffected by CPAP [13], we now demonstrate a decrease
in TNFA after CPAP use. Both results confirm an earlier
report [24]. Our findings that CPAP decreased TNF
independent of changes in adipose tissue suggest that
intermittent hypoxia [21, 27], the immediate decrease in
sympathetic output [28] have stronger impact upon inflam-
matory cytokines than fat. A decrease in TNFA after
6 months septoplasty and uvulo-palato-pharyngoplasty
without changes in BMI supports this hypothesis [29].
Our observation that TNFA decreased even in patients
using CPAP for less than 4 h/night and who had a lower
AHI, and thus, a less severe disease suggests that the effect
of CPAP on TNFA could also be a function of disease
severity. Given that low adherence is frequently associated
with low severity [20] and that we found a small but
significant dose–response relationship of nightly CPAP use
with changes in TNFA levels, our data suggest that also
men with low AHI at baseline benefit from CPAP use.
Our study has several limitations. First, we did not
include a control group and the effects of CPAP. However,
given the beneficial effects of CPAP on a large variety of
cardiovascular outcomes variables [30] and in addition on
quality of life [31] during the initial design of the study and
from a clinical perspective, it seemed unethical to withhold
ventilation to a larger patient population over such a long
period of time: To date, several sham trials with a duration
of up to 6 months are underway. In addition, the number of
women studied and the number of non-compliant patients is
relatively small and results in non-compliant persons are
likely to differ from patients in a true control or sham
ventilation group. Therefore, conclusions drawn for women
should be interpreted with caution, and the small sample
size might have influenced our results. Furthermore, this
observational study was initially planned to assess changes
in body composition after 6 months of CPAP use. Thus, our
sample size and the different mean baseline ODI and AHI data
between the two groups might have been underpowered to
detect the effect of adherence with CPAP on TNFA. However,
studies on the effects of CPAP on visceral fat or TNF, either
report results in men or did not report the sex of the patients
[12, 24, 32], while others included a very small number of
women [10] (n=3).
In summary, our study demonstrated that baseline
hypoxemia during PSG did not predict serum TNFA
concentrations, but 8 months of CPAP decreased serum
TNFA without—as previously shown, affecting body fat
mass suggesting that other factors than adipose tissue or
reversal of hypoxia modulate the beneficial effects of CPAP
on inflammatory cytokines. Future studies should attempt
to recruit more women and additionally assess longitudinal
changes in body composition, inflammation, and metabolism
in both genders affected by this disease. Given that CPAP
decreased TNFA also in men with low adherence and the fact
that we found a small but significant association of nightly
CPAP > 4h/night CPAP < 4h/night-2.5
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CPAP use with changes of TNFA, patients with lower
adherence should be motivated to use CPAP as frequently
and long as possible.
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